Korean J Med.
2004 Jul;67(1):94-99.
A case of posttransplantation lymphoproliferative disease developed in renal transplant recipient and treated with rituximab
- Affiliations
-
- 1Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea. ahnmj@hanyang.ac.kr
- 2Department of Pathology, Hanyang University College of Medicine, Seoul, Korea.
Abstract
- Posttransplant lymphoproliferative disorder (PTLD) are among the most serious and potentially fatal complications of chronic immunosuppression in organ transplant recipient and also the most common malignancies, accounting for 21 percent of all malignancies in organ transplants versus 5 percent of malignancies in the general population. PTLD is associated with immunosuppression and Epstein Barr virus (EBV). Treatment modality of PTLD includes antiviral agent, interferon, intensive chemotherapy and monoclonal antibody. Choice of treatment modality depends on clinical presentation of PTLD. We report here a case of PTLD involving liver and renal allograft treated with rituximab.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Post-transplant Lymphoproliferative Disorder in Transplanted Kidney Causing Urinary Tract Obstruction
- A Case of Successful Third Renal Transplantation Using Rituximab (anti-CD20 Monoclonal Antibody) in a Highly Sensitized Patient
- Posttransplant Lymphoproliferative Disorder without Epstein-Barr Virus Presented as Small Bowel Perforation in Renal Transplant Recipient: A Case Report
- Cerebral Post-Transplant Lymphoproliferative Disorder Occurring after Renal Transplantation: A Case Report
- Epstein-Barr Virus Related Polymorphic Posttransplantation Lymphoproliferative Disease in a Patient with Latent Infection of JC Virus
